Results 1 to 10 of about 16,006 (139)

Discovery and development of Factor Xa inhibitors (2015–2022) [PDF]

Frontiers in Pharmacology, 2023
As a pathological coagulation process, thrombus can lead to many serious diseases, including ischemic stroke, acute myocardial infarction (AMI), acute coronary syndrome (ACS), and deep venous thrombosis (DVT).
Wei Zheng, Wei Zheng, Xiaoqin Dai, Binyao Xu, Wei Tian, Jianyou Shi   +5 more
doaj   +2 more sources

Expedited surgery does not increase transfusion rates for patients with geriatric hip fracture taking factor Xa inhibitors [PDF]

OTA International, 2023
. Objectives:. Geriatric patients who sustain hip fractures and are taking factor Xa inhibitors (Xa-I) experience surgical delay. Our institution developed a pharmacokinetic protocol to formally guide and expedite surgical timing for these patients.
Juntian Wang, MD, Paal Nilssen, BS, Julia Stone, BS, Kathleen Breda, MSN, BBA, RN, AGACNP-BC, ONP-C, Milton Little, MD, Charles Moon, MD, Carol Lin, MD   +6 more
doaj   +2 more sources

Three cases of neutralization of factor Xa inhibitors with andexanet alfa under rotational thromboelastography monitoring [PDF]

Acute Medicine & Surgery
Background Factor Xa inhibitors are direct oral anticoagulants that are extremely useful in clinical applications, safe, and do not require dose adjustment.
Takeshi Yagi, Reina Kawano, Takuto Tomokage, Ryo Ayata, Yasutaka Koga, Kotaro Kaneda, Motoki Fujita, Nanami Yamanaka, Naomasa Mori, Ryosuke Tsuruta   +9 more
doaj   +2 more sources

Efficacy of Factor Xa Inhibitors Versus Placebo in Thromboprophylaxis for Cancer-Associated Thromboembolism: A Systematic Review and Meta-analysis [PDF]

Clinical and Applied Thrombosis/Hemostasis
Background Cancer patients are at significantly increased risk of venous thromboembolism (VTE), a leading cause of morbidity and mortality in this population.
Amna Kamil MBBS, Sandhiya Prem Kumar MBBS, Rumaisa Zulfiqar MBBS, Eiman Araib MBBS, Bibi Samia Khan MBBS, Muhammad Saad Khan MBBS, Muhammad Mohsin Khan MBBS, Umaimah Naeem MBBS, Aminath Waafira MBBS   +8 more
doaj   +2 more sources

Direct factor Xa inhibitors and the risk of cancer and cancer mortality: A Danish population-based cohort study. [PDF]

PLoS Medicine
BackgroundPreclinical animal studies have suggested that myeloid cell-synthesized coagulation factor X dampens antitumor immunity and that rivaroxaban, a direct factor Xa inhibitor, can be used to promote tumor immunity. This study was aimed at assessing
Floris Bosch, Erzsébet Horváth-Puhó, Suzanne C Cannegieter, Nick van Es, Henrik T Sørensen   +4 more
doaj   +2 more sources

Predictors of hematoma expansion in intracerebral hemorrhage associated with factor Xa inhibitors [PDF]

Frontiers in Neurology
BackgroundImproving the outcomes of patients with intracerebral hemorrhage (ICH) associated with factor Xa inhibitors remains a clinical challenge. Andexanet alfa, a specific reversal agent for factor Xa inhibitors, has the potential to mitigate hematoma
Yoji Komatsu, Takao Koiso, Tomokazu Sekine, Kazuki Akutagawa, Kazuki Akutagawa, Hiroki Karita, Hiroki Karita, Norie Kikuchi, Tomosato Yamazaki, Tomosato Yamazaki   +9 more
doaj   +2 more sources

Efficacy and Toxicity of Factor Xa Inhibitors

Journal of Pharmacy & Pharmaceutical Sciences, 2013
Venous thromboembolism (VTE) is a serious disease that is often neglected, and effective and safe antithrombotic treatments are a public health priority.
Maryna Bondarenko, Christophe Curti, Marc Montana, Pascal Rathelot, Patrice Vanelle   +4 more
doaj   +5 more sources

Monitoring anti-factor Xa activity in patients with chronic thromboembolic pulmonary hypertension treated with factor Xa inhibitors [PDF]

Scientific Reports
Direct oral anticoagulants (DOACs) have been used clinically in patients with chronic thromboembolic pulmonary hypertension (CTEPH) for secondary prevention after acute venous thromboembolism, although the data are limited.
Yoshihisa Nakano, Shiro Adachi, Miku Hirose, Takeshi Adachi, Itsumure Nishiyama, Kenichiro Yasuda, Masahiro Yoshida, Takahisa Kondo, Toyoaki Murohara   +8 more
doaj   +2 more sources

Factor Xa Inhibitors Versus Vitamin K Antagonists in Atrial Fibrillation Patients with End-Stage Kidney Disease on Dialysis: A Meta-Analysis [PDF]

Clinical and Applied Thrombosis/Hemostasis
Background Atrial fibrillation (AF) is prevalent among patients with end-stage kidney disease (ESKD) undergoing dialysis, and both conditions are associated with a heightened risk of cardiovascular diseases.
Meimei Xiong MS, Linjuan Guo MD, Yun Wan MS   +2 more
doaj   +2 more sources

Clinical Pathways and Outcomes of Andexanet Alfa Administration for the Reversal of Critical Bleeding in Patients on Oral Direct Factor Xa Inhibitors [PDF]

TH Open
Background Andexanet is U.S. Food and Drug Administration (FDA) approved for the reversal of critical bleeding from factor Xa inhibitors and off-label for surgical reversal. Data are lacking on andexanet administration processes.
Mark Goldin, Kolton Smith, Ioannis Koulas, Tungming Leung, Mayuri Ravi, Sanjit Parhar, Sejal Shah, Kayla Floyd, Lori Ohanesian, Rachel Bain, Daniella Defonte, Kanta Ochani, Amanda Lin, Bhumi Patel, Nikolaos Tsaftaridis, Jack Jnani, Alex C. Spyropoulos   +16 more
doaj   +2 more sources